H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Oncternal Therapeutics to $18 from $19 and keeps a Buy rating on the shares following the Q2 report. The firm is taking higher operating expenses into account.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCT:
- Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
- ONCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results
- One new option listing and eighteen option delistings on July 22nd
- Oncternal completes enrollment, dosing in Phase 1/2 study of ONCT-534